

## Buprenorphine Formulations Commercially Available as of March 2025

Product	Combo or Mono	Route	Indication	Max Dosage
<b>Buprenorphine/Naloxone</b>	Combo	SL Tablet	OUD	24/6 mg/day
<b>Suboxone<sup>®</sup></b>	Combo	SL/Buccal Film	OUD	24/6 mg/day
<b>Zubsolv<sup>®</sup></b>	Combo	SL Tablet	OUD	17.2/4.2 mg/day
<b>Buprenorphine</b>	Mono	SL Tablet	OUD	24 mg/day
<b>Subutex<sup>®</sup></b>	Mono	SL Tablet	OUD	24 mg/day
<b>Sublocade<sup>®</sup></b>	Mono	ER/SQ Injection	OUD	300 mg monthly x 2, then 100 mg monthly thereafter
<b>Brixadi<sup>®</sup></b> (Weekly or Monthly)	Mono	ER/SQ Injection	OUD	32 mg/week (weekly) or 128 mg/month (monthly)